Japanese
English
- 有料閲覧
- Abstract 文献概要
- 1ページ目 Look Inside
- 参考文献 Reference
要約 目的:網膜中心静脈閉塞症に対するベバシズマブの硝子体内投与の報告。対象と方法:黄斑浮腫を伴う網膜中心静脈閉塞症14例14眼を対象とした。男性9例,女性5例で,年齢は62~88歳(平均74歳)である。logMAR視力は平均1.00±0.75であった。ベバシズマブ1.25mgを硝子体内に注射し,6か月以上の経過を追った。結果:最終視力は平均0.57±0.50で,治療前よりも有意に改善した(p<0.05)。中心窩網膜厚の平均値は,治療前758±179μm,治療後296±236μmで,有意に減少した(p<0.01)。12眼には複数回の治療が行われた。治療前の中心窩網膜厚が700μm以上の8眼では平均4.9回,これ以下の4眼では平均2.7回で,有意差があった(p<0.05)。結論:黄斑浮腫を伴う網膜中心静脈閉塞症へのベバシズマブの硝子体内投与で視力の向上が得られた。難治または再発例には複数回の投与が必要であった。
Abstract. Purpose:To report the outcome of intravitreal injection of bevacizumab in eyes with central retinal vein occlusion(CRVO). Cases and Method:This study was made on 14 eyes of 14 patients of CRVO with macular edema. The series comprised 9 males and 5 females. The age ranged from 62 to 88 years,average 74 years. Visual acuity was expressed as logMAR. Bevacizumab was injected in the vitreous at the dosis of 1.25 mg per session. Cases were followed up for 6 months or longer. Results:Final visual acuity increased to 0.57±0.50 from the pretreatment level of 1.00±0.75. The difference was significant(p<0.05). Foveal thickness decreased from 758±179μm before treatment to 296±236μm at the last visit. The difference was significant(p<0.01). Eight eyes with foveal thickness of 700μm or over received an average of 4.9 injections. Four eyes with lesser thickness received 2.7 injections. The difference was significant(p<0.05). Conclusion:Intravitreal bevacizumab was followed by improved visual acuity in eyes with CRVO with macular edema. Severe or persistent cases needed repeat injections.
Copyright © 2010, Igaku-Shoin Ltd. All rights reserved.